Search: Tilray

Tilray to Announce First Quarter Fiscal 2022 Financial Results on October 7, 2021

NEW YORK & LEAMINGTON, Ontario–(BUSINESS WIRE)–Tilray, Inc. (“Tilray” or the “Company”) (NASDAQ: TLRY; TSX: TLRY) announced that the Company will release financial results for its first quarter fiscal 2022 ended August 31, 2021 before financial markets open on Thursday, October 7, 2021. Tilray executives will host a conference call and live audio webcast to discuss these results at 8:30 am…

Tilray Inc. Sends Open Letter to Shareholders

Tilray Inc (NASDAQ: TLRY) sent an open letter on August 26 from Irwin D. Simon, CEO and chairman, to the company’s shareholders. In the letter, Simon describes his vision for the company and gives his $4 billion target. He also encourages shareholders to vote for initiatives that are in line with this vision at Tilray’s special meeting of stockholders. The meeting…

Tilray Has a Lot of Potential if the U.S. Legalizes Cannabis

But that is no guarantee for TLRY stock While Canada becoming the first G7 nation to legalize recreational marijuana represented a boon for cannabis firms like Tilray (NASDAQ:TLRY), the long-term goal has always been breaking into the U.S. Let’s face facts. With a population of under 38 million, Canada just doesn’t have the economic clout that stakeholders of TLRY stock are looking…

Why Aurora Cannabis, Tilray, and Sundial Growers Stocks Tumbled on Thursday

What happens if marijuana isn’t the only drug that gets legalized in the US? What happened Marijuana stocks got thrown for a loop on Thursday, and shares of Aurora Cannabis (NASDAQ:ACB) are trading down 3.6% as of 3:40 p.m. EDT, followed by Sundial Growers (NASDAQ:SNDL) with a 4% loss, and Tilray (NASDAQ:TLRY) down 4.4%. So what It’s rarely easy to put your finger on what exactly causes a marijuana stock to go up…

Tilray Buys Stake In MedMen For $165 Million

  Tilray, Inc. (NASDAQ: TLRY) has bought the majority of the outstanding senior secured convertible notes of MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF) that were originally held by certain funds affiliated with Gotham Green Partners, LLC and other funds. The transaction is valued at $165.8 million. Tilray said the purchase sets the company up to own a significant equity position in MedMen…

Tilray to Exchange 9 Million Shares for $165.8 Million Convertible Note and Warrant Position Held by Gotham Green Partners

Tilray Acquires Majority Position in Amended MedMen Convertible Notes Investment Provides Tilray a Potential Accelerated Path into U.S. Cannabis Market Upon Federal Legalization Amendment and Extension of Convertible Notes Enables MedMen to Reshape Balance Sheet and Further Accelerate its Growth Trajectory Tilray and MedMen CEOs to Host a Conference Call and Webcast at 5:00 PM […] READ MORE: https://www.newcannabisventures.com/tilray-to-exchange-9-million-shares-for-165-million-convertible-note-and-warrant-position-held-by-gotham-green-partners/

Irwin Simon Maps Out Path to Tilray’s Potential $4 Billion in Revenue by 2024

Exclusive Interview with Tilray Chairman and CEO Irwin Simon The merger of Tilray (NASDAQ: TLRY) (TSX: TLRY) and Aphria closed in May of this year, and now, the combined company is working on growing brands and expanding its business in Canada, Europe and the U.S. Chairman and CEO Irwin Simon last spoke with New Cannabis […] READ MORE: https://www.newcannabisventures.com/irwin-simon-maps-out-path-to-tilrays-potential-4-billion-in-revenue-by-2024/